|Articles|April 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2001
  • Volume 0
  • Issue 0

Liberated?

Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.

Articles in this issue

over 24 years ago

Regulation: Two-Track Plan

over 24 years ago

Policy: Tectonic Shift

over 24 years ago

A Matter of Taste

over 24 years ago

Partnerships: Bargaining Biotechs

over 24 years ago

Pediatric Mandate

over 24 years ago

Genentech's Passion for Patients

over 24 years ago

Regulation: OK After All

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.